We demonstrated that N-arachidonoyl taurine (N-AT), a PUFA analog, restores gating, at least partly, in all these tested LQTS mutants, suggesting N-AT could be a novel KNCQ1/KCNE1 activator for LQTS treatment. The gene discussed is KCNE1; the disease is familial long QT syndrome.